Welcome to our dedicated page for CALITHERA BIOSCIENCES news (Ticker: CALA), a resource for investors and traders seeking the latest updates and insights on CALITHERA BIOSCIENCES stock.
Calithera Biosciences Inc. (CALA) is a pioneering biopharmaceutical company dedicated to the discovery and development of first-in-class small molecule drugs aimed at slowing tumor growth. Their approach focuses on controlling key metabolic pathways in both tumor and immune cells, targeting the distinct metabolic requirements of these cells to impede cancer proliferation.
Calithera leverages the promising fields of tumor metabolism and tumor immunology to create new, innovative cancer therapies. Recent clinical successes highlight the potential of their investigational medicines to slow abnormal cell growth and offer fundamentally new treatment options for cancer patients.
Currently, Calithera's lead candidate is in Phase 2 trials for patients with renal cell carcinoma and triple negative breast cancer. These trials are crucial given the urgent need for new treatments in these solid tumors.
Calithera also engages in strategic partnerships to bolster its research and development efforts. Their onco-metabolism approach aims to bring a fresh perspective to cancer treatment by exploiting the unique metabolic needs of cancer cells versus cancer-fighting immune cells.
For more information, latest updates, and significant news regarding Calithera Biosciences Inc., visit their official webpage or contact them directly.
Calithera Biosciences announces topline results from the CANTATA trial for its drug telaglenastat in advanced renal cell carcinoma, which failed to meet its primary endpoint of improving progression-free survival compared to cabozantinib. The hazard ratio was 0.94 with a median PFS of 9.2 months. Following the results, Calithera plans to reduce its workforce by 35% to focus on ongoing trials, including the KEAPSAKE trial for non-small cell lung cancer. The company projects cash reserves of $115 million should sustain operations through 2022 and anticipates severance costs of $1.3-$1.5 million.
Calithera Biosciences (Nasdaq: CALA) announced the grant of a non-qualified stock option to a new employee for 50,000 shares at an exercise price of $4.91, equivalent to the closing trading price on December 31, 2020. The option vests one-fourth in December 2021, with the remainder vesting in thirty-six monthly installments. This grant complies with Nasdaq Listing Rule 5635(c)(4) and is part of the 2018 Inducement Plan. Calithera specializes in developing targeted therapies for cancer treatment.
Calithera Biosciences (CALA) announced the granting of non-qualified stock options for 53,000 shares to three new employees. The exercise price is set at $4.91 per share, based on the closing price on November 30, 2020. One-fourth of the options will vest in November 2021, with the remainder vesting in 36 equal monthly installments. This grant is part of the Inducement Plan approved by the board in January 2018, in compliance with Nasdaq rules. Calithera focuses on developing targeted therapies for cancer and other serious diseases.
Calithera Biosciences (Nasdaq: CALA) announced participation in two healthcare investor conferences in November 2020. On November 18, CEO Susan M. Molineaux will present at the Jefferies Virtual Healthcare Conference at 2:20 p.m. ET, with a live webcast available for replay for 30 days.
Additionally, Calithera will host virtual investor meetings on November 19 at the SVB Leerink Oncology 1x1 Day. The company focuses on developing targeted therapies for cancer and is committed to expanding treatment options for patients.
Calithera Biosciences has revealed promising preclinical data on its IL4I1 inhibitor, CB-668, which shows significant immune-mediated anti-tumor activity. This oral small-molecule inhibitor targets IL4I1, an enzyme that hinders anti-tumor immunity. Presented at the SITC Virtual Annual Meeting, findings indicate CB-668 enhances pro-inflammatory gene expression and exhibits tolerance at effective doses in animal studies. The compound is poised for further development as it is seen as having potential benefits for various cancers, especially ovarian tumors and B cell lymphomas.
Calithera Biosciences (CALA) announced its Q3 2020 financial results, reporting a net loss of $22.7 million, or $0.32 per share. Cash reserves stood at $137.7 million. Significant progress includes advancements in clinical trials for its lead candidate, telaglenastat, with top-line results from the pivotal CANTATA trial expected in late Q4 2020 or early Q1 2021. New trials for telaglenastat in non-small cell lung cancer and the arginase inhibitor for cystic fibrosis also commenced. R&D expenses increased by $1 million year-over-year due to ongoing program investments.
Calithera Biosciences announced the expansion of its clinical trial evaluating telaglenastat in combination with palbociclib for patients with pancreatic ductal adenocarcinoma (PDAC) featuring KRAS and CDKN2A mutations. This Phase 1/2 study aims to assess safety and anti-tumor activity in a new cohort of advanced PDAC patients. Previous trials showed promising efficacy of the treatment combination, suggesting a potential improvement in treatment options for this hard-to-treat cancer.
Calithera Biosciences (CALA) announced the granting of non-qualified stock options to three new employees, totaling 138,500 shares at an exercise price of $3.54. The options will vest over time, with one-fourth vesting after a year and the remainder in thirty-six monthly installments. This grant aligns with Nasdaq Listing Rule 5635(c)(4) and is part of Calithera's 2018 Inducement Plan. The company is focused on developing novel therapies for cancer treatment. Future statements regarding progress and safety of product candidates are subject to risks, impacting stock performance.
Calithera Biosciences (CALA) has received up to $2.4 million from the Cystic Fibrosis Foundation to advance clinical development of CB-280, a first-in-class arginase inhibitor targeting cystic fibrosis. This funding aims to enhance nitric oxide levels to combat infections in cystic fibrosis patients. The ongoing randomized clinical study (NCT04279769) evaluates the safety and efficacy of CB-280 compared to a placebo in adults with chronic Pseudomonas aeruginosa infection. Interim data is expected in 2021, marking a significant step in addressing unmet needs in cystic fibrosis treatment.
Calithera Biosciences (CALA) is set to announce its third quarter 2020 financial results on November 5, 2020. A conference call will be held the same day at 2:00 p.m. PT to discuss the results and recent corporate highlights. The press release emphasizes Calithera's commitment to developing targeted therapies for cancer treatment, highlighting its pipeline of oral therapeutics. Forward-looking statements in the release caution investors about potential risks in clinical trials and regulatory approvals that may affect the company's stock performance.
FAQ
What is the market cap of CALITHERA BIOSCIENCES (CALA)?
What does Calithera Biosciences Inc. specialize in?
What is the primary focus of Calithera's research?
What are Calithera's lead candidates currently being tested for?
How does Calithera's onco-metabolism approach work?
What recent achievements has Calithera accomplished?
Who can I contact for more information about Calithera?
Where can I find the latest updates on Calithera?
What kind of partnerships does Calithera engage in?
Why is Calithera's research important?
What makes Calithera's therapy approach unique?
